Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07731607) titled 'Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer' on July 22.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Wang Jianliu
Condition:
MMRd Endometrial Cancer of Stage I~II
Intervention:
Drug: Sintilimab monotherapy
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: July 20, 2026
Target Sample Size: 48
To know more, visit https://clinicaltrials.gov/study/NCT07731607
Published by HT Digital Content Services with permission...